Convection-enhanced delivery of targeted toxins for malignant glioma

Expert Opinion on Drug Delivery

Volumn 3, Issue 3, 2006, Pages 371-377

  Hall, Walter A ^a   Sherr, Gregory T ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Brain neoplasm; Convection enhanced delivery; Glioma; Targeted toxin

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR DIPHTHERIA TOXIN; IMMUNOTOXIN; INTERLEUKIN 13 PSEUDOMONAS EXOTOXIN; INTERLEUKIN 4 PSEUDOMONAS EXOTOXIN; PACLITAXEL; TP 38; TRANSFERRIN DIPHTHERIA TOXIN; TRANSFORMING GROWTH FACTOR ALPHA PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BRAIN RADIATION; BRAIN SURGERY; CATHETER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; INFUSION PUMP; MAXIMUM PERMISSIBLE DOSE; MEAN RESIDENCE TIME; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; THERMODYNAMICS; TREATMENT PLANNING;

ANIMALS; CLINICAL TRIALS; CONVECTION; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTOXINS; MAGNETIC RESONANCE IMAGING;

EID: 33646828478     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.3.371     Document Type: Review

References (41)

1. WESTPHAL M, BLACK PM: Perspective of cellular and molecular neurosurgery. J. Neurooncol. (2004) 70(2):257-271.
2. HALL WA, RUSTAMZADEH E, ASHER AL: Convection-enhanced delivery in clinical trials. Neurosurg. Focus (2003) 14(2):e2.
3. DEBINSKI W: Local treatment of brain tumours with targeted chimaera cytotoxic proteins. Cancer Invest. (2002) 20(5-6):801-809.
4. BOIARDI A, EOLI M, SALMAGGI A et al.: Local drug delivery in recurrent malignant gliomas. Neurol. Sci. (2005) 26(Suppl. 1):S37-S39.
5. WEBER FW, FLOETH F, ASHER A et al.: Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta. Neurochir. Suppl. (2003) 88:93-103.
6. VOGELBAUM MA: Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J. Neurooncol. (2005) 73(1):57-69.
7. LASKE DW, ILERCIL O, AKBASAK A et al.: Efficacy of direct intra-tumoural therapy with targeted protein toxins for solid human gliomas in nude mice. J. Neurosurg. (1994) 80:520-526.
8. PRABHU SS, BROADDUS WC, GILLIES CT, LOUDON WG, CHEN ZJ, SMITH B: Distribution of macromolecular dyes in brain using positive pressure infusion: a model for direct controlled delivery of therapeutic agents. Surg. Neurol. (1998) 50(4):367-375.
9. BOBO RH, LASKE DW, AKBASAK A, MORRISON PF, DEDRICK RL, OLDFIELD EH: Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA (1994) 91(6):2076-2080.
10. LIEBERMAN DM, LASKE DW, MORRISON PF, BANKIEWICZ KS, OLDFIELD EH: Convection-enhanced distribution of large molecules in grey matter during interstitial drug infusion. J. Neurosurg. (1995) 82(6):1021-1029.
11. CHEN MY, LONSER RR, MORRISON PF, GOVERNALE LS, OLDFIELD EH: Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J. Neurosurg. (1999) 90(2):315-320.
12. CHEN ZJ, BROADDUS WC, VISWANATHAN RR, RAGHAVAN R, GILLIES GT: Intraparenchymal drug delivery via positive-pressure infusion: experimental and modeling studies of poroelasticity in brain phantom gels. IEEE Trans. Biomed. Eng. (2002) 49(2):85-96.
13. CHEN ZJ, GILLIES GT, BROADDUS WC et al.: A realistic brain tissue phantom for intraparenchymal infusion studies. J. Neurosurg. (2004) 101(2):314-322.
14. DEGEN JW, WALBRIDGE S, VORTMEYER AO, OLDFIELD EH, LONSER RR: Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J. Neurosurg. (2003) 99(5):893-898.
15. MARDOR Y, RAHAV O, ZAUBERMAN Y et al.: Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res. (2005) 65(15):6858-6863.
16. OCCHIOGROSSO C, EDGAR MA, SANDBERG DI, SOUWEIDANE MM: Prolonged convection-enhanced delivery into the rat brainstem. Neurosurgery (2003) 52(2):388-393.
17. GROOTHUIS DR: The blood-brain and blood-tumour barriers: a review of strategies for increasing drug delivery. Neuro-oncol. (2000) 2(1):45-59.
18. KROLL RA, PAGEL MA, MULDOON LL, ROMAN-GOLDSTEIN S, NEUWELT EA: Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery (1996) 4:746-752.
19. LONSER RR, WALBRIDGE S, GARMESTANI K et al.: Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J. Neurosurg. (2002) 97(4):905-913.
20. MARDOR Y, ROTH Y, LIDAR Z et al.: Monitoring response to convection-enhanced taxol delivery in brain tumour patients using diffusion-weighted magnetic resonance imaging. Cancer Res. (2001) 61(13):4971-4973.
21. CROTEAU D, WALBRIDGE S, MORRISON PF et al.: Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. J. Neurosurg. (2005) 102(1):90-97.
22. NGUYEN TT, PANNU YS, SUNG C et al.: Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J. Neurosurg. (2003) 98(3):584-590.
23. VOGES J, RESZKA R, GOSSMANN A et al.: Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. (2003) 54(4):479-487.
24. CHIOCCA EA, BROADDUS WC, GILLIES GT, VISTED T, LAMFERS ML: Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J. Neurooncol. (2004) 69(1-3):101-117.
25. KAWAKAMI K, KAWAKAMI M, KIOI M, HUSAIN SR, PUPI RK: Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J. Neurosurg. (2004) 101(6):1004-1011.
26. KUNWAR S: Convection enhanced delivery of 1L13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing Phase I studies. Acta. Neurochir. Suppl. (2003) 88:105-111.
27. COHEN KA, LIU T, BISSONETTE R, PUPI RK, FRANKEL AE: DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr. Pharm. Biotechnol. (2003) 4(1):39-49.
28. SAMPSON JH, AKABANI C, ARCHER GE et al.: Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumours. J. Neurooncol. (2003) 65(1):27-35.
29. WEBER F, ASHER A, BUCHOLZ R et al.: Safety, tolerability, and tumour response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J. Neurooncol. (2003) 64(1-2):125-137.
30. KAWAKAMI M, KAWAKAMI K, PURI RK: Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J. Neurooncol. (2003) 65(1):15-25.
31. LEVY RM, MAJOR E, ALI MJ, COHEN B, GROOTHIUS D: Convection-enhanced intraparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephalopathy (PML). J. Neurovirol. (2001) 7(4):382-385.
32. MERLO A, HAUSMANN O, WAGNER M et al.: Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labelled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin. Cancer Res. (1999) 5:1025-1033.
33. YANG W, BARTH RF, ADAMS DM et al.: Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor positive gliomas. Cancer Res. (2002) 62(22):6552-8.
34. TRASK TW, TRASK RP, AGUILAR-CORDOVA E et al.: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors Mol. Ther. (2000) 1:195-203.
35. WERSALL P, OHLSSON I, BIBERFELD P et al.: Intratumoural infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol. Immunother. (1997) 44(3):157-164.
36. FONG TA, SHAWVER LK, SUN L, TANG C, APP H, POWELL TJ et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumour vascularization and growth of multiple tumour types. Cancer Res. (1999) 59(1):99-106.
37. LAIRD AD, VAJKOCZY P. SHAWVER LK, THURNHER A, HANG C, MOHAMMADI M et al.: Su6668 is a potent antiangiogenic and antitumour agent that induces regression of established tumours. Cancer Res. (2000) 60(15):4152-4160.
38. GARBER K: Angiogenesis inhibitors suffer new setback. Nat. Biotechnol. (2002) 20(11):1067-1068.
39. MARSHALL E: Cancer therapy. Setbacks for endostatin. Science (2002) 295(5563):2198-2199.
40. MACKAY JA, DEEN DF, SZOKA FC Jr: Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res. (2005) 1035(2):139-153.
41. GRADY MS, HOWARD MA III, DACEY RG Jr, BLUME W, LAWSON M, WEP P, RITTER RC: Experimental study of the magnetic stereotaxis system for catheter manipulation within the brain. J. Neurosurg (2000) 93:282-288.